The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should omidubicel become SOC for umbilical cord blood transplantation?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Guillermo Sanz, Hospital Universitari i Politècnic La Fe, Valencia, ES. We asked, Should omidubicel become standard of care (SOC) for umbilical cord blood transplantation?

Should omidubicel become SOC for umbilical cord blood transplantation?

In this video, Sanz discusses the outcomes of a phase III randomized study focusing on omidubicel, an ex vivo expanded cord blood product. The trial compared the efficacy of omidubicel to standard umbilical cord blood transplantation in patients with hematologic malignancies. Results suggest neutrophil engraftment was faster with omidubicel and the clinical benefits were greater.

 

Share: